Holen Sie sich die Stockscreener-App
3.945
2.72%
-0.115
Schlusskurs vom Vortag:
$4.06
Offen:
$4
24-Stunden-Volumen:
527.48K
Relative Volume:
0.27
Marktkapitalisierung:
$280.83M
Einnahmen:
$26.87M
Nettoeinkommen (Verlust:
$-137.06M
KGV:
-2.0673
EPS:
-1.9083
Netto-Cashflow:
$-125.25M
1W Leistung:
+11.57%
1M Leistung:
-0.77%
6M Leistung:
+174.27%
1J Leistung:
+229.13%
1-Tages-Spanne:
$3.92
$4.125
1-Wochen-Bereich:
$3.46
$4.33
52-Wochen-Spanne:
$1.13
$6.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Firmenname
Zentalis Pharmaceuticals Inc
Sektor
Branche
Telefon
(858) 263-4333
Adresse
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
3.945 | 289.02M | 26.87M | -137.06M | -125.25M | -1.9083 |
VRTX
Vertex Pharmaceuticals Inc
|
436.69 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.59 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.19 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.62 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.32 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2024-08-12 | Hochstufung | Wedbush | Underperform → Neutral |
| 2024-06-20 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-06-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | Herabstufung | Wedbush | Neutral → Underperform |
| 2024-06-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | Eingeleitet | Cowen | Outperform |
| 2022-04-06 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-29 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-01-20 | Eingeleitet | Wedbush | Outperform |
| 2020-09-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-28 | Eingeleitet | Guggenheim | Buy |
| 2020-04-28 | Eingeleitet | Jefferies | Buy |
| 2020-04-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Zentalis Pharmaceuticals Inc Aktie (ZNTL) Neueste Nachrichten
ZNTL: Azenosertib shows promising efficacy and safety in ovarian cancer, with pivotal data expected this year - TradingView
Zendesk Inc (ZEN) - Minichart
H.C. Wainwright Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $10 - Moomoo
H.C. Wainwright reiterates Zentalis stock rating on ovarian cancer data By Investing.com - Investing.com Canada
ZNTL Stock Price, Quote & Chart | ZENTALIS PHARMACEUTICALS INC (NASDAQ:ZNTL) - ChartMill
Zentalis Pharmaceuticals Presents Promising Phase 1b MUIR Trial Results of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 9 - Minichart
Zentalis to present ovarian cancer trial data at ASCO meeting By Investing.com - Investing.com Australia
Phase 1b ovarian cancer data for Zentalis (NASDAQ: ZNTL) azenosertib combo - Stock Titan
Zentalis Pharmaceuticals Announces Promising Phase 1b Results for Azenosertib Plus Paclitaxel in Ovarian Cancer at ASCO 2026 - Quiver Quantitative
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 - GlobeNewswire
Zentalis Pharmaceuticals (ZNTL) price target increased by 19.05% to 5.83 - MSN
ZNTL SEC FilingsZentalis Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
What's behind the surge in Zentalis stock? - MSN
Immunome Inc stock (US45254C1062): oncology deal momentum keeps biotech in focus - AD HOC NEWS
A Quick Look at Today's Ratings for Zentalis Pharmaceuticals(ZNTL.US), With a Forecast Between $5 to $10 - Moomoo
Zentalis Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $6.5, Implies 52% Upside - TradingView
Oppenheimer Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - 富途牛牛
Zentalis: Buy Rating Reiterated as Azenosertib Strategy Advances; $10 Price Target Maintained on De-Risked Dosing and Late-Stage Catalysts - TipRanks
Zentalis Pharmaceuticals 1Q Loss/Shr 50c >ZNTL - Moomoo
TradingKey - TradingKey
Is Zentalis Pharmaceuticals (ZNTL) Attractive After Q1 2026 Earn - GuruFocus
ZNTL Advances Key Trials for Ovarian Cancer Treatment - GuruFocus
ZNTL: Azenosertib shows >30% ORR in Cyclin E1-positive PROC, targeting a major unmet need - TradingView
Zentalis Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Zentalis Advances Azenosertib with New Trial Updates - TipRanks
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress - The Manila Times
Zentalis (ZNTL) trims Q1 loss as azenosertib moves into Phase 3 - Stock Titan
Zentalis Pharmaceuticals, Inc. 1Q 2026: Net income $(35.4)M, EPS $(0.50) — 10-Q Summary - TradingView
Zentalis (Nasdaq: ZNTL) trims Q1 2026 loss while pushing azenosertib toward pivotal ovarian cancer milestones - Stock Titan
Press Release: Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress - Moomoo
Zentalis Pharmaceuticals Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Zentalis begins phase 3 trial of ovarian cancer drug By Investing.com - Investing.com South Africa
Zentalis Starts Pivotal Phase 3 ASPENOVA Ovarian Cancer Trial - TipRanks
Zentalis begins phase 3 trial of ovarian cancer drug - Investing.com
Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer - The Manila Times
Zentalis starts global Phase 3 ovarian cancer trial against chemotherapy - Stock Titan
Zentalis doses first patient in Phase 3 ASPENOVA trial for Cyclin E1-positive PROC - TradingView
Phase 3 ovarian cancer trial starts for Zentalis (Nasdaq: ZNTL) drug azenosertib - Stock Titan
Zentalis Pharmaceuticals Announces First Patient Dosed in - GlobeNewswire
Zentalis Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(4) - marketscreener.com
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Zentalis hire gets 26,000 stock options at $4.09 a share - Stock Titan
[ARS] Zentalis Pharmaceuticals, Inc. SEC Filing - Stock Titan
Zentalis (ZNTL) schedules 2026 virtual meeting on directors, auditor and executive pay - Stock Titan
Zentalis Pharmaceuticals (ZNTL) Price Target Decreased by 14.14% to 5.42 - MSN
ZNTL Should I Buy - Intellectia AI
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer - The Manila Times
Zentalis Pharmaceuticals Announces Abstract Acceptance at - GlobeNewswire
Ovarian cancer drug combo data lands June ASCO presentation - Stock Titan
Finanzdaten der Zentalis Pharmaceuticals Inc-Aktie (ZNTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zentalis Pharmaceuticals Inc-Aktie (ZNTL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer |
Feb 09 '26 |
Sale |
2.39 |
335 |
802 |
33,332 |
| Vultaggio Vincent | PAO and PFO |
Feb 06 '26 |
Sale |
2.43 |
29,951 |
72,772 |
156,779 |
| Vultaggio Vincent | PAO and PFO |
Feb 10 '26 |
Sale |
2.42 |
6,894 |
16,699 |
146,506 |
| Vultaggio Vincent | PAO and PFO |
Feb 09 '26 |
Sale |
2.39 |
3,379 |
8,086 |
153,400 |
| EASTLAND JULIA MARIE | CEO & President |
Feb 06 '26 |
Sale |
2.43 |
7,866 |
19,112 |
80,022 |
| EASTLAND JULIA MARIE | CEO & President |
Feb 09 '26 |
Sale |
2.39 |
889 |
2,127 |
79,133 |
| Vultaggio Vincent | PAO and PFO |
Feb 02 '26 |
Sale |
2.55 |
2,540 |
6,477 |
187,286 |
| Vultaggio Vincent | PAO and PFO |
Feb 03 '26 |
Sale |
2.52 |
556 |
1,398 |
186,730 |
| WALTERS GROUP | 10% Owner |
Dec 31 '25 |
Buy |
1.20 |
6,459,973 |
7,751,968 |
13,509,973 |
| Matrix Capital Management Comp | 10% Owner |
Dec 15 '25 |
Sale |
1.33 |
7,500,000 |
9,975,000 |
6,459,973 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):